Introduction {#s1}
============

Solid organ transplantation is expensive and exerts a huge financial burden on transplant recipients. The average reported cost of a solid organ transplant ranges from \$334,300 for a single kidney transplant to more than \$2.3 million for combined heart and lung transplants ([@B1]). The use of immunosuppressive medications after transplantation is essential for the success of organ transplantation because immunosuppressive regimens can reduce acute rejection rates and graft loss resulting from acute rejection ([@B19]). In the early 1980s, cyclosporine, a calcineurin inhibitor, was introduced in the market and provided excellent renal graft survival rates ([@B27]; [@B4]). This agent impairs the transcription of interleukin-2 and several other cytokines in T lymphocytes ([@B11]). However, cyclosporine may lead to adverse reactions such as nephrotoxicity, chronic hemolytic uremic syndrome, hyperlipidemia, hypertension, gingival hyperplasia, diabetes mellitus, and tremors. Since its Food and Drug Administration (FDA) approval in the early 1990s, tacrolimus has been widely used as an alternative immunosuppressive medication after all types of solid organ transplants; it is a more potent calcineurin inhibitor. Compared with cyclosporine, tacrolimus provides lower acute rejection rates and potentially higher graft survival rates, as demonstrated by several randomized controlled trials and meta-analyses; however, tacrolimus is associated with a higher risk of posttransplant diabetes mellitus ([@B4]; [@B14]; [@B28]). Tacrolimus may plausibly result in additional costs of managing adverse events and increase the non-transplant-related health service utilization of transplant recipients.

Until now, few studies have estimated the healthcare service utilization of stable heart, kidney, and liver transplant recipients receiving different calcineurin inhibitors. Studies have shown that compared with cyclosporine, tacrolimus-based immunosuppression is associated with economic advantages among kidney or liver transplant recipients due to its lower acute rejection rates ([@B15]; [@B21]; [@B25]; [@B16]; [@B20]). However, cost-effectiveness analyses in Brazil and Germany have revealed that tacrolimus treatment entails higher total health service expenditures than cyclosporine treatment after renal transplantation ([@B12]; [@B7]). Previous reports have indicated inconsistent economic impacts of calcineurin inhibitors on the healthcare system. In addition, to date, no study has explored healthcare service utilization in heart transplant recipients receiving calcineurin inhibitors. Thus, this population-based study investigated the differences in healthcare service utilization among stable heart, kidney, and liver transplant recipients receiving cyclosporine or tacrolimus-based treatment during a 1-year follow-up period in Taiwan.

Materials and Methods {#s2}
=====================

Database {#s2_1}
--------

This study used data of the de-identified medical claims from the Taiwan National Health Insurance Research Database (NHIRD). This database includes medical records and registry files for approximately 99% of the Taiwanese population (*n* = 23 million) since 1995. The NHIRD has been released to investigators in Taiwan for research purposes, and researchers are permitted to track the longitudinal records of the enrollees. The need for ethics approval was waived by the Tri-Service General Hospital Institutional Review Board because it only used de-identified secondary data. The data sets for this manuscript are not publicly available, because the data are handled and stored by the Health and Welfare Data Science Center (HWDC). Requests to access the data sets should be directed to the HWDC, Department of Statistics, Ministry of Health and Welfare, Taiwan (<http://dep.mohw.gov.tw/DOS/np-2497-113.html>).

Study Sample {#s2_2}
------------

In this nationwide cross-sectional study, 3,902 transplant recipients (including heart, kidney, and liver transplant recipients) receiving cyclosporine or tacrolimus between 1 January 2011 and 31 December 2011 were first identified. The use of the study drug was determined on the basis of the Anatomical Therapeutic Chemical codes (L04AD01 for cyclosporine and L04AD02 for tacrolimus). Generally, given that acute rejection mostly occurs within weeks to 1 year after transplantation, the index date was defined as the last date on which patients received cyclosporine or tacrolimus during the study period to minimize the acute rejection factor. To ensure equal follow-up periods among all selected stable transplant recipients, we excluded 175 patients who died within the study period after the index date. We further excluded 245 patients aged \<18 years to ensure that adult transplant recipients were recruited. Accordingly, 3,482 transplant recipients receiving cyclosporine or tacrolimus were recruited into this study. In addition, 2,741 tacrolimus users were identified as the study group, and 741 cyclosporine users were defined as the comparison group. We further divided the study patients into three groups: heart transplant recipients, kidney transplant recipients, and liver transplant recipients.

Variables of Interest {#s2_3}
---------------------

In order to carry out the healthcare service utilization assessments and evaluate patients' healthcare service visits and costs, all transplant recipients in this study were tracked for 1 year following the index date. Healthcare service in this study included those of physician diagnoses, medications, surgery, and laboratory tests covered by National Health Insurance (NHI) program. Variables of outpatient service utilization during the 1-year follow-up period in this study were defined as follows: 1) mean numbers of outpatient visits, 2) mean total costs of outpatient services, 3) mean costs of outpatient study drugs (cyclosporine and tacrolimus), and 4) mean costs of other outpatient services (excluding costs of study drugs to avoid the effects due to different drug prices between cyclosporine and tacrolimus). Variables of inpatient service utilization were identified as follows: 1) mean numbers of inpatient days, 2) mean total costs of inpatient services, 3) mean costs of inpatient study drugs, and 4) mean costs of other inpatient services (excluding costs of study drugs to avoid the effects due to different drug prices between cyclosporine and tacrolimus). Additionally, variables of all NHI healthcare services' costs were defined as follows: 1) mean total costs, 2) mean costs of study drugs, and 3) mean costs of other healthcare services (excluding costs of study drugs to avoid the effects due to different drug prices between cyclosporine and tacrolimus).

Statistical Analysis {#s2_4}
--------------------

Pearson chi-squared tests were conducted to compare the differences in sex, urbanization level (five levels, with 1 being the most urbanized and 5 being the least urbanized), monthly income, transplanted organs, and comorbidities between cyclosporine and tacrolimus users ([@B17]). Independent *t* tests were performed to compare the differences in the utilization and costs between cyclosporine and tacrolimus users. A two-sided *p* value of \<0.05 was used to evaluate statistical significance. All statistical analyses were performed using the SAS system (version 9.4, SAS System for Windows).

Results {#s3}
=======

This study included a total of 3,482 stable transplant recipients who received tacrolimus or cyclosporine. Among the sampled transplant recipients in this study, 2,741 were defined as tacrolimus users, and 741 were identified as cyclosporine users. The demographic characteristics and comorbidities of the sampled patients are presented in [**Table 1**](#T1){ref-type="table"}. The mean age of tacrolimus and cyclosporine users was 50.2 ± 11.6 and 50.2 ± 11.4 years, respectively (p = 0.912). Although the mean number of years after transplantation was statistically fewer in tacrolimus users (3.7 ± 2.9 years) than in cyclosporine users (4.9 ± 3.2 years), the time after transplantation was sufficiently long to consider these recipients as being relatively stable. Other findings revealed that the distributions of sex, hypertension, hyperlipidemia, coronary heart disease, arrhythmia, thyroid disease, anxiety, and transplanted organ were significantly different between tacrolimus and cyclosporine users. However, no significant difference was observed in age, urbanization level, monthly income, and diabetes between the two groups.

###### 

Demographic characteristics of tacrolimus and cyclosporine users (*N* = 3,482).

  ----------------------------------------------------------------------------------------------------
  Variable                     Tacrolimus users\   Cyclosporine users\   *p* value           
                               (*n* = 2,741)       (*n* = 741)                               
  ---------------------------- ------------------- --------------------- ----------- ------- ---------
  Age (years)                  50.2 ± 11.6         50.2 ± 11.4           0.912               

  Sex                                                                                        0.001

   Male                        1,716               62.6                  413         55.7    

   Female                      1,025               37.4                  328         44.3    

  Urbanization level                                                                         0.050

   1 (most urbanized)          836                 30.5                  262         35.4    

   2                           810                 29.6                  199         26.9    

   3                           454                 16.6                  125         16.9    

   4                           361                 13.2                  77          10.4    

   5 (least urbanized)         280                 10.2                  78          10.5    

  Monthly income                                                                             0.548

   US\$0--US\$600              1,104               40.3                  304         41.0    

   US\$601--US\$1,200          1,054               38.5                  293         39.5    

   ≥US\$1,201                  583                 21.3                  144         19.4    

  Transplanted organ                                                                         \<0.001

   Heart                       208                 7.6                   169         22.8    

   Kidney                      1,254               45.8                  439         59.2    

   Liver                       1,279               46.7                  133         18.0    

  Year after transplantation   3.7 ± 2.9           4.9 ± 3.2             \<0.001             

  Comorbidities                                                                              

   Hypertension                1,043               38.1                  206         27.8    \<0.001

   Hyperlipidemia              1,699               62.0                  428         57.8    0.036

   Diabetes                    1,843               67.2                  481         64.9    0.233

   Coronary heart disease      1,985               72.4                  465         62.8    \<0.001

   Arrhythmia                  2,214               80.77                 502         67.75   \<0.001

   Thyroid disease             1,020               37.21                 403         54.39   \<0.001

   Anxiety                     1,345               49.07                 264         35.63   \<0.001
  ----------------------------------------------------------------------------------------------------

[**Table 2**](#T2){ref-type="table"} presents the utilization and costs of outpatient services, inpatient services, and all healthcare services within the 1-year study period following the index date for transplant recipients receiving cyclosporine or tacrolimus. Regarding outpatient service utilization, tacrolimus users had a significantly higher number of outpatient visits (40.7 vs. 38.6) and total outpatient costs (US\$10,383 vs. US\$8,155) than cyclosporine users. However, no significant difference was observed in inpatient days and total inpatient costs between tacrolimus and cyclosporine users. Additionally, regarding all healthcare services, tacrolimus users had higher total costs (US\$12,516 vs. US\$10,372) than cyclosporine users.

###### 

Utilization and costs of outpatient services, inpatient services, and all healthcare services within 1 year for tacrolimus and cyclosporine users (*N* = 3,482).

  --------------------------------------------------------------------------------------------------------
  Variable                         Tacrolimus users\   Cyclosporine users\   *p* value           
                                   (*n* = 2,741)       (*n* = 741)                               
  -------------------------------- ------------------- --------------------- ----------- ------- ---------
  Outpatient services                                                                            

   Outpatient visits (no.)         40.7                19.3                  38.6        18.9    0.009

   Total outpatient costs (US\$)   10,383              9,825                 8,155       4,609   \<0.001

  Inpatient services                                                                             

   Inpatient days (no.)            7.4                 21.7                  8.2         19.4    0.332

   Total inpatient costs (US\$)    2,133               6,952                 2,217       6,192   0.749

  All NHI healthcare services                                                                    

   Total costs (US\$)              12,516              12,459                10,372      8,562   \<0.001
  --------------------------------------------------------------------------------------------------------

SD, standard deviation.

NHI, National Health Insurance

[**Table 3**](#T3){ref-type="table"} presents the total health service utilization, outpatient service utilization, and inpatient service utilization within 1 year for tacrolimus and cyclosporine users among heart, kidney, and liver transplant recipients. Among heart transplant recipients, tacrolimus users had a significantly higher number of outpatient visits (37.3 vs. 32.2), total outpatient costs (US\$11,991 vs. US\$9,407), outpatient study drug costs (US\$4,197 vs. US\$2,394), total inpatient costs (US\$4,729 vs. US\$2,737), inpatient study drug costs (US\$202 vs. US\$119), and other inpatient costs (US\$4,527 vs. US\$2,618) than cyclosporine users. Regarding all healthcare service utilization among heart transplant recipients, tacrolimus users had significantly higher total costs (US\$16,720 vs. US\$12,144), study drug costs (US\$4,399 vs. US\$2,513), and other costs (US\$12,321 vs. US\$963) than cyclosporine users.

###### 

Utilization and costs of healthcare services within 1 year for cyclosporine and tacrolimus users, stratified by different transplantations.

  Variable                         Heart transplant recipients (*n* = 377)   Kidney transplant recipients (*n* = 1,693)   Liver transplant recipients (*n* = 1,412)                                                                                
  -------------------------------- ----------------------------------------- -------------------------------------------- ------------------------------------------- ----------------- --------------- --------- ---------------- --------------- ---------
  Outpatient services                                                                                                                                                                                                                              
   Outpatient visits (no.)         37.3 (19.8)                               32.2 (16.0)                                  0.005                                       41.0 (18.9)       40.5 (18.6)     0.624     40.8 (19.5)      40.3 (21.5)     0.767
   Total outpatient costs (US\$)   11,991 (5,997)                            9,407 (5,131)                                \<0.001                                     10,378 (12,726)   7,978 (4,182)   \<0.001   10,125 (6,471)   7,146 (4,939)   \<0.001
    Study drug costs               4,197 (3,091)                             2,394 (1,056)                                \<0.001                                     4,003 (2,797)     2,120 (1,574)   \<0.001   3,321 (2,463)    1,995 (1,054)   \<0.001
    Other outpatient costs         7,794 (4,989)                             7,013 (5,107)                                0.136                                       6,375 (12,563)    5,858 (4,091)   0.202     6,805 (5,694)    5,151 (4,777)   \<0.001
  Inpatient services                                                                                                                                                                                                                               
    Inpatient days (no.)           11.7 (27.4)                               10.3 (23.6)                                  0.591                                       6.2 (18.0)        6.9 (16.3)      0.415     7.8 (23.9)       9.6 (22.6)      0.422
   Total inpatient costs (US\$)    4,729 (10,403)                            2,737 (5,286)                                0.017                                       1,735 (6,248)     2,011 (6,779)   0.453     2,102 (6,823)    2,237 (5,136)   0.780
    Study drug costs               202 (379)                                 119 (298)                                    0.018                                       66 (202)          45 (145)        0.016     94 (360)         84 (254)        0.686
    Other inpatient costs          4,527 (10,219)                            2,618 (5,035)                                0.019                                       1,668 (6,113)     1,967 (6,696)   0.412     2,008 (6,613)    2,153 (4,970)   0.757
  All NHI healthcare services                                                                                                                                                                                                                      
   Total costs (US\$)              16,720 (12,203)                           12,144 (7,924)                               \<0.001                                     12,113 (14,770)   9,989 (9,010)   \<0.001   12,227 (9,574)   9,384 (7,499)   \<0.001
    Study drug costs               4,399 (3,238)                             2,513 (1,180)                                \<0.001                                     4,070 (2,829)     2,164 (1,604)   \<0.001   3,415 (2,523)    2,079 (1,140)   \<0.001
    Other costs                    12,321 (11,763)                           9,631 (7,650)                                0.008                                       8,044 (14,703)    7,825 (9,002)   0.714     8,812 (8,996)    7,304 (7,240)   0.027

SD, Standard deviation.

Among kidney transplant recipients ([**Table 3**](#T3){ref-type="table"}), tacrolimus users had higher total costs and study drug costs for outpatient services and all healthcare services than cyclosporine users. In addition, tacrolimus users had higher inpatient study drug costs than cyclosporine users. [**Table 3**](#T3){ref-type="table"} also shows the utilization of liver transplant recipients. The findings revealed that tacrolimus users had higher total costs (US\$10,125 vs. US\$7,146), study drug costs (US\$3,321 vs. US\$1,995), and other costs (US\$6,805 vs. US\$5,151) for outpatient services than cyclosporine users. Furthermore, regarding all healthcare services, tacrolimus users had higher total costs (US\$12,227 vs. US\$9,384), study drug costs (US\$3,415 vs. US\$2,079), and other costs (US\$8,812 vs. US\$7,304) than cyclosporine users.

Discussion {#s4}
==========

This population-based study found that stable transplant recipients receiving tacrolimus had higher healthcare service utilization, including outpatient visits, outpatient costs, and total costs of all NHI healthcare services, than transplant recipients receiving cyclosporine ([**Table 2**](#T2){ref-type="table"}). The higher outpatient visits among tacrolimus users than among cyclosporine users may be caused by the high prevalence of some chronic diseases, including hypertension, hyperlipidemia, and coronary heart disease, in tacrolimus users ([**Table 1**](#T1){ref-type="table"}). A possible explanation is that tacrolimus might be preferred for patients with hypertension, sodium retention, and hypercholesterolemia. Additionally, cyclosporine might be the more favorable choice for patients with diabetes mellitus, and it has milder neurological side effects ([@B3]; [@B24]; [@B28]; [@B8]). Therefore, stable transplant recipients receiving tacrolimus may experience more comorbidities, including hypertension, hyperlipidemia, and coronary heart disease, than cyclosporine users, thereby resulting in more outpatient visits. Moreover, no difference was observed in the distribution of diabetes mellitus between tacrolimus and cyclosporine users ([**Table 1**](#T1){ref-type="table"}), although previous studies have found that patients receiving tacrolimus had a higher incidence of *de novo* insulin-requiring diabetes mellitus ([@B28]; [@B8]). This finding might be explained reasonably by the fact that cyclosporine is more commonly prescribed for transplant recipients with diabetes mellitus. Furthermore, unsurprisingly, outpatient study drug costs in tacrolimus users were higher than those in cyclosporine users in this study due to the higher actual wholesale price of tacrolimus ([@B10]). Our findings are in agreement with those of previous economic studies indicating that regimens containing cyclosporine were more cost-effective than tacrolimus-based regimens in renal transplant recipients ([@B6]; [@B12]; [@B7]).

In the United States, previous studies comparing cyclosporine with tacrolimus in renal transplant recipients concluded that tacrolimus use led to higher cost savings because of the lower rates of hospitalization as a result of fewer acute rejection episodes ([@B10]; [@B13]). However, our study found no difference in days and total costs of inpatient services between stable transplant recipients receiving tacrolimus and those receiving cyclosporine in Taiwan ([**Table 2**](#T2){ref-type="table"}). It is reasonably speculated that a similar rate of graft survival was observed among stable transplant recipients regardless of the use of different study drugs after the acute rejection period ([@B22]; [@B23]; [@B29]). In Brazil, Gomes et al. showed poorer graft survival rates (survival rates of 64.8% and 71.9%, respectively) and increased risk of death or return to dialysis (hazard ratio = 1.194; 95% CI 1.082--1.318) in patients treated with tacrolimus compared with those treated with cyclosporine after a 10-year follow-up ([@B5]). Therefore, different ethnicities may contribute to consistent outcomes from these studies.

To the best of our knowledge, this is the first study to provide a real-world assessment of healthcare service utilization, including complete utilization information and medical costs, among stable heart transplant recipients receiving calcineurin inhibitors through analysis of the nationwide population-based data set NHIRD. To date, studies on healthcare service utilization among heart transplant recipients receiving different calcineurin inhibitors are limited. Studies have indicated that heart transplant recipients treated with cyclosporine presented higher rates of cytomegalovirus infection ([@B26]), thereby increasing the need for treatment by approximately eightfold ([@B2]), than those treated with tacrolimus. Compared with tacrolimus as baseline immunosuppressive therapy, cyclosporine may also produce higher risks of obesity ([@B18]) and a more pronounced deterioration of renal function ([@B9]) after heart transplantation. The abovementioned side effects of cyclosporine may be a key factor for the increase in healthcare service utilization. However, among stable heart transplant recipients, we found that tacrolimus users had approximately five more outpatient visits than cyclosporine users. Regarding inpatient services, although no difference was observed in the number of inpatient days between heart transplant recipients receiving tacrolimus and those receiving cyclosporine, tacrolimus users had approximately 1.7-fold higher total inpatient costs, especially nonstudy drug--related costs, than cyclosporine users ([**Table 3**](#T3){ref-type="table"}).

Several limitations of this study should be considered. First, this study did not evaluate self-paid healthcare services (such as over-the-counter medicines) and indirect costs in transplant recipients. Secondly, many undocumented factors may potentially affect the utilization and costs of healthcare services in this study. Third, the study findings should be generalized to other ethnicities with discretion because most of the patients included in this study were Chinese Han.

In conclusion, this population-based study revealed that stable transplant recipients receiving tacrolimus had higher outpatient healthcare service utilization than those receiving cyclosporine. Additionally, heart transplant recipients receiving tacrolimus had approximately 1.7-fold higher total costs of inpatient healthcare services than those receiving cyclosporine, but no difference was noted in inpatient days within the 1-year study period following the index date between transplant recipients receiving cyclosporine and those receiving tacrolimus. Based on the study results, we suggest that physicians should consider the economic impact of tacrolimus on lower-income stable transplant recipients, especially heart transplant recipients. Additional studies should be conducted to further investigate the potential factors leading to elevated healthcare service utilization by stable transplant recipients receiving tacrolimus.
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